Calton & Associates’s Corbus Pharmaceuticals CRBP Stock Holding History

Calton & Associates’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-7	Closed	-$1K	–	514
2017 Q4	$1K	Buy	+7	New	+$1.5K	﹤0.01%	1432

Other funds holding CRBP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Calton & Associates's CRBP Position: Q1 2018 in Review

Calton & Associates sold out of Corbus Pharmaceuticals (CRBP) in Q1 2018, closing a stake of 7 shares — an estimated $1K sold.

Calton & Associates first reported a position in CRBP in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 81 funds tracked by Wall St. Rank hold CRBP as of Q1 2018.

Calton & Associates reported no remaining Corbus Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 7 Corbus Pharmaceuticals shares in Q1 2018, an estimated $1K.
Calton & Associates first reported a position in Corbus Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Calton & Associates's Corbus Pharmaceuticals position peaked at $1K in Q4 2017.
81 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.